Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 18.54% is 37% below its 2-year average of 29.58%, near the low end of its 2-year range (13.06%–81.20%).
As of the fiscal period ended Tuesday, June 30, 2026. 0.05% below its 12-month average of 18.55%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 18.54%.
DEBT TO ASSETS RATIO
18.54%
DEBT TO ASSETS RATIO AVG TTM
18.55%
DEBT TO ASSETS RATIO AVG 3Y
N/A
DEBT TO ASSETS RATIO AVG 5Y
N/A
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-0.05%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11%
median of 465 covered companies
CURRENT VS SECTOR MEDIAN
+16756.35%
vs the sector median at left
Carlsmed, Inc.
Market Cap
$415.93M
Debt to Assets Ratio
18.54%
TTM Avg
18.55%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$416.68M
Debt to Assets Ratio
0.10%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$410.54M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$408.21M
Debt to Assets Ratio
0.32%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$406.47M
Debt to Assets Ratio
0.10%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$428.16M
Debt to Assets Ratio
0.07%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$447.43M
Debt to Assets Ratio
0.25%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$450.64M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$453.70M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Carlsmed, Inc. (CARL) | $415.93M | 18.54% | 18.55% | N/A | N/A |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $416.68M | 0.10% | N/A | N/A | N/A |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $410.54M | 0.00% | N/A | N/A | N/A |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $408.21M | 0.32% | N/A | N/A | N/A |
| Shoulder Innovations, Inc. (SI)vs › | $406.47M | 0.10% | N/A | N/A | N/A |
| Editas Medicine, Inc. (EDIT)vs › | $428.16M | 0.07% | N/A | N/A | N/A |
| Capricor Therapeutics, Inc. (CAPR)vs › | $447.43M | 0.25% | N/A | N/A | N/A |
| Assembly Biosciences, Inc. (ASMB)vs › | $450.64M | 0.01% | N/A | N/A | N/A |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $453.70M | 0.00% | N/A | N/A | N/A |
| Canopy Growth Corporation (CGC)vs › | $373.40M | 0.25% | N/A | N/A | N/A |
Debt/Assets
18.5%
Debt/Equity
0.26
Current Ratio
8.84
Interest Coverage
-21.4x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 18.54% |
| 2026-03-31 | 14.53% |
| 2025-12-31 | 13.38% |
| 2025-09-30 | 13.06% |
| 2025-06-30 | 33.24% |
| 2025-03-31 | 29.54% |
| 2024-12-31 | 33.15% |
| 2023-12-31 | 81.20% |
